Bragar Eagel & Squire remind investors of Unicycive, Nutex Health, Snap class actions.

Bragar Eagel & Squire, a shareholder rights law firm, has filed class action lawsuits on behalf of investors in Unicycive, Nutex Health, and Snap. The lawsuits claim that the companies made false or misleading statements to investors, including about their drug applications and manufacturing compliance. Investors have until October 14, 2025, to petition the court to serve as lead plaintiff.

Shareholder rights law firm Bragar Eagel & Squire has recently filed class action lawsuits against Unicycive Therapeutics, Inc., Nutex Health Inc., and Snap, Inc., alleging that these companies made false or misleading statements to investors. The lawsuits claim that the companies overstated their drug applications' regulatory prospects and their readiness to satisfy FDA manufacturing compliance requirements.

Unicycive Therapeutics, Inc.

The lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) alleges that the company made materially false and misleading statements about its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application. These statements were alleged to have been overstated, leading to artificial inflation of the company's stock. Investors who purchased shares between March 29, 2024, and June 27, 2025, are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment for a class action lawsuit [1].

Nutex Health Inc.

The lawsuit against Nutex Health Inc. (NASDAQ: NUTX) alleges that the company made materially false and misleading statements about its revenues derived from HaloMD's engagement in the IDR process and its ability to remediate material weaknesses in its internal controls over financial reporting. Investors who purchased Nutex securities between August 8, 2024, and August 14, 2025, are encouraged to join this class action lawsuit [2].

Snap Inc.

While no specific details about the lawsuit against Snap Inc. are provided in the source materials, it is implied that the company is also facing a class action lawsuit alleging false or misleading statements.

Investors in all three companies have until October 14, 2025, to petition the court to serve as lead plaintiff. The lead plaintiff will represent the interests of all shareholders who were affected by the alleged misrepresentations.

Next Steps

Investors who believe they may be eligible to join these class action lawsuits are encouraged to contact the respective law firms listed in the source materials. The lawsuits seek to recover losses on behalf of investors who were adversely affected by the alleged securities fraud.

References

[1] https://www.ainvest.com/news/unicycive-therapeutics-lawsuit-filed-alleged-misleading-statements-2508/
[2] https://www.morningstar.com/news/globe-newswire/9519463/unicycive-therapeutics-inc-sued-for-securities-law-violations-contact-levi-korsinsky-before-october-14-2025-to-discuss-your-rights-uncy